Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02951312 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Glycopyrrolate Inhalation Solution 25mg
DRUG: Glycopyrrolate Inhalation Solution 75mg
DRUG: Glycopyrrolate Inhalation Solution 200mg
DRUG: Glycopyrrolate Inhalation Solution 200mg Jet
DRUG: Glycopyrrolate Inhalation Solution 500mg
DRUG: Glycopyrrolate Inhalation Solution1000mg
DRUG: Placebo

Sponsor

Sunovion Respiratory Development Inc.